The renewed strength in TAVR, following a slowdown last year tied to heart team capacity challenges at hospitals, prompted ...

Edwards Lifesciences Corporation EW reported second-quarter 2025 adjusted earnings per share (EPS) of 67 cents, which ...

Edwards Lifesciences has lifted its 2025 profit outlook to between 9%-10%, up from 8%-10%, amid strong Q2 2025 performance in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral ...

Background Current risk scores inadequately predict long-term mortality after transcatheter aortic valve replacement (TAVR), ...

Edwards Lifesciences stock surged late Thursday after the medtech hiked its outlook following a key setback for rival Boston ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights. Q2 sales g ...

Edwards Lifesciences EW is gaining from the robust uptake of its premium surgical technologies. The company’s Transcatheter ...

JenaValve announced today that it began patient enrollment in the ARTIST study evaluating its Trilogy TAVR system.

Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) provides an alternative treatment for high-risk patients with failed surgical bioprosthetic aortic valves. However, limited data exist ...

Simulations using post-TAVR CT imaging show that redo-TAV is more feasible in patients with bicuspid aortic valves compared to tricuspid aortic valves, according to new research published in JACC: ...